Drugs / TPN-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05613868 | Mar 2023 → Feb 2025 | Aicardi-Goutieres syndrome | Transposon Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04993768 | Dec 2021 → Feb 2024 | progressive supranuclear palsy | Transposon Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04993755 | Oct 2021 → Aug 2023 | amyotrophic lateral sclerosis, frontotemporal dementia | Transposon Therapeutics, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-08-27 | Oncolys BioPharma Inc | Results LINE-1 阻害剤センサブジン（OBP-601）の oncolys.com ↗ |
| 2024-12-04 | Oncolys BioPharma Inc | Results International Symposium on ALS/MNDにおける OBP-601 の oncolys.com ↗ |
| 2024-11-07 | Oncolys BioPharma Inc | Results Annual ALS Research Symposium における OBP-601 の oncolys.com ↗ |
| 2024-10-11 | Oncolys BioPharma Inc | Results 2024 Annual NEALS Meeting における OBP-601 の oncolys.com ↗
Based on these promising results, we are advancing TPN -101 into a Phase 3 registrational study for the treatment of C9orf72 -related ALS, while also continuing to develop TPN -101 for other neurodegenerative diseases. |
| 2024-07-25 | Oncolys BioPharma Inc | Results OBP-601（censavudine, TPN-101）の C-9 ALS Phase2a 試験の oncolys.com ↗ |
| 2024-05-22 | Oncolys BioPharma Inc | Regulatory 進行性核上性麻痺（PSP）における OBP-601（censavudine, TPN-101）の oncolys.com ↗ |
| 2024-02-14 | Oncolys BioPharma Inc | Results OBP-601（censavudine, TPN-101）の PSP Phase2a 試験に関する最終解析結果、 oncolys.com ↗
OBP-601 は、PSP 患者において神経変性の主要なバイオマーカーである脳脊髄液中の NfL 値（ニューロフィラメント軽鎖）の上昇を抑制することが確認されました。 |
| 2023-11-15 | Oncolys BioPharma Inc | Results AD/PD 2024（国際アルツハイマー・パーキンソン病学会）における oncolys.com ↗ |
| 2021-08-16 | Oncolys BioPharma Inc | Regulatory Announcement of FDA Clearance of Two IND Applications to Initiate Phase 2 Clinical Trials of OBP-601 (Censavudine, TPN-101) oncolys.com ↗ |
| 2021-08-16 | Oncolys BioPharma Inc | Regulatory OBP-601（Censavudine, TPN-101）の神経変性疾患を対象とした oncolys.com ↗ |
All press releases naming this drug 19 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04993768 ↗ |